If you have been reading about clinical development and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Dissolution behavior depends on the amino acid sequence, the counterion content, and the buffer chosen. Many peptides disperse readily in water or mild aqueous buffers, while others require a small amount of organic co-solvent or a change in pH. Adsorption to plastic and glass surfaces can reduce the concentration of a solution over time, particularly at low concentrations. Filtration before analysis removes particulates, and aliquoting limits repeated freeze-thaw cycles that stress the material.
Research-grade peptide material is commonly supplied as a lyophilized powder, a form that limits degradation during transport and storage. Standard practice keeps such material cold and protected from light and moisture, with tighter conditions used for long-term archives. Once dissolved, solutions are generally considered less stable than the dry powder and are handled on shorter timescales. These established conventions derive largely from general peptide chemistry rather than from compound-specific evidence alone.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
As a peptide, the compound is generally supplied as a lyophilized powder and stored frozen to slow degradation. Recommended conditions usually sit at minus twenty degrees Celsius or colder, shielded from light and moisture. Solutions are less stable than the dry powder and are often prepared fresh before analysis. Repeated freeze-thaw cycles can drive aggregation, so splitting stock material into small aliquots reduces handling stress and preserves sample integrity.
Quality control of research material relies on several complementary checks. Purity testing confirms the absence of truncated or oxidized peptide species, while water content and counterion analysis show how much mass comes from salts rather than the peptide itself. Sequence verification through tandem mass spectrometry ensures the correct amino acid chain. Because unregulated suppliers vary widely, independent verification of identity and purity is often necessary before a sample enters experiments.
Documentation plays a practical role in maintaining consistent results across laboratories. Certificates of analysis list purity, identity, and testing methods, and batch numbers allow comparisons between lots. Records of storage temperature and handling history help investigators interpret unexpected findings. When a sample behaves anomalously, reviewing that documentation often reveals whether the cause lies in the material or in the assay conditions.
In February 2018, logistics mismanagement by DHL, which had been selected by KFC UK as their new delivery partner, caused a chicken shortage in the United Kingdom – KFC's largest market in Europe – forcing the company to temporarily close hundreds of restaurants around the country. KFC apologized by taking out adverts in British newspapers showing the company's initials rearranged to read "FCK", followed by an apology, which was well received. In November 2021, Finland's first KFC restaurant was opened at the Itis shopping center in Itäkeskus, Helsinki. A few days before the opening day, a tent had appeared in front of the restaurant, where a man who had kept his identity secret for a few days had stayed, and who on the opening day revealed himself to the public as a vegan activist defending animal rights. After trying to give his speech to those present, the security company carried him away. Even before the opening of the restaurant, in October, news of a controversy over the procurement of a broiler for food from Poland; the cause is mainly related to the risk of salmonella in broilers, which is a significant problem in Poland, whereas its prevalence in Finland is low. Following the 2022 Russian invasion of Ukraine, a number of companies have faced growing pressure to halt operations in Russia but have not yet done so. This includes KFC, which has over 1,000 outlets in Russia, more than any other Western fast food chain. However, within a few years, all Russian KFC restaurants were rebranded as "Rostic's".
The effects of 2C-B were reported by Shulgin to include sensory enhancement, brightened colors, visual richness, mental imagery, psychedelic visuals including kaleidoscopic and organic forms, sound distortion, increased appreciation of art and music, passivity, relaxation, emotional changes, euphoria, increased body awareness, tactile enhancement, feeling like waves of energy are flowing through oneself, feeling like one's body is flooded with orgasms, and sexual enhancement. He has succinctly described 2C-B as having "a luxury of sensory enhancement (visual, sexual, gustatory) with a minimum of introspective demands". The drug was one of his favorite psychedelics and one of his "magical half-dozen" most important psychedelic phenethylamines. At doses of 8 to 10 mg, 2C-B was described as consistently producing substantial sensory enhancement, but as not "superimposing hallucinogenesis" or as having "no hallucinogenic effects", with the state being described as quite distinct from that usually associated with psychedelics. It was also said to lack the lassitude that can be associated with psilocybin.
== Career == McLain provides voices for many characters in several video games from Valve. Among them are GLaDOS, the primary antagonist of the Portal video game series (for which she won an AIAS Interactive Achievement Award for Outstanding Achievement in Character Performance), the announcer in Team Fortress 2, and the voice of the Combine Overwatch for the Half-Life series. McLain sang "Still Alive" and "Want You Gone", the ending credits songs to Portal and Portal 2, respectively, both of which were written by Jonathan Coulton. She also sang "Cara Mia Addio" at the end of Portal 2. In December 2011, McLain won the Spike Video Game Award in the category "Best Performance by a Human Female" for her voice acting as GLaDOS in Portal 2. In 2013, she lent her public support to gathering donations for the Kickstarter-funded LGBT gaming convention GaymerX. She later was a special guest at the convention in August 2013. In 2014, she portrayed Fairy Godmother in the online video series [Wish It Inc.]. In 2015, she portrayed Lisa Clarke in the gay independent film, Winning Dad. This film was also promoted on McLain's YouTube channel. McLain has played roles in many radio dramas on the radio program Imagination Theatre. In 2021, McLain provided the voice of GLaDOS non-canonically, singing a verse in The Chalkeaters’ song "Count to Three" as a cameo.
In environmental terms, the residence time definition is adapted to fit with ground water, the atmosphere, glaciers, lakes, streams, and oceans. More specifically it is the time during which water remains within an aquifer, lake, river, or other water body before continuing around the hydrological cycle. The time involved may vary from days for shallow gravel aquifers to millions of years for deep aquifers with very low values for hydraulic conductivity. Residence times of water in rivers are a few days, while in large lakes residence time ranges up to several decades. Residence times of continental ice sheets is hundreds of thousands of years, of small glaciers a few decades. Ground water residence time applications are useful for determining the amount of time it will take for a pollutant to reach and contaminate a ground water drinking water source and at what concentration it will arrive. This can also work to the opposite effect to determine how long until a ground water source becomes uncontaminated via inflow, outflow, and volume. The residence time of lakes and streams is important as well to determine the concentration of pollutants in a lake and how this may affect the local population and marine life. Hydrology, the study of water, discusses the water budget in terms of residence time. The amount of time that water spends in each different stage of life (glacier, atmosphere, ocean, lake, stream, river), is used to show the relation of all of the water on the earth and how it relates in its different forms.
Sources: en.wikipedia.org
=== Pain === Ketamine infusions are used for acute pain treatment in emergency departments and in the perioperative period for individuals with refractory or intractable pain. The doses are lower than those used for anesthesia, usually referred to as sub-anesthetic doses. Adjunctive to morphine or on its own, ketamine reduces morphine use, pain level, nausea, and vomiting after surgery. Ketamine is likely to be most beneficial for surgical patients when severe post-operative pain is expected, and for opioid-tolerant patients. Ketamine is especially useful in the pre-hospital setting due to its effectiveness and low risk of respiratory depression. Ketamine has similar efficacy to opioids in a hospital emergency department setting for the management of acute pain and the control of procedural pain. It may also prevent opioid-induced hyperalgesia and postanesthetic shivering. For chronic pain, ketamine is used as an intravenous analgesic, mainly if the pain is neuropathic. It has the added benefit of counteracting spinal sensitization or wind-up phenomena experienced with chronic pain. In multiple clinical trials, ketamine infusions delivered short-term pain relief in neuropathic pain diagnoses, pain after a traumatic spine injury, fibromyalgia, and complex regional pain syndrome (CRPS).
=== United States === The seaweed has been found in several harbors in southern California. In May 2009 it was discovered in San Francisco Bay and aggressive efforts are underway to remove it before it spreads.
== Research and pipeline == In 2025, Novo tested whether semaglutide helped slow progression for Alzheimer's disease. However, on November 24, 2025, the company announced that the studies failed to find any effect of the drug on cognition and functioning in people with mild cognitive impairment or with dementia. Novo was researching pulmonary delivery systems for diabetic medications, and in the early stages of research into autoimmune and chronic inflammatory diseases, using technologies such as translational immunology and monoclonal antibodies. In September 2014, the company announced a decision to discontinue all research in inflammatory disorders, including the discontinuation of R&D in anti-IL-20 for the treatment of rheumatoid arthritis. In September 2018, it was reported that the company would lay off 400 administrative staff, laboratory technicians and scientists, in Denmark and China in order to concentrate research and development efforts on "transformational biological and technological innovation".
== V == V3 loop – vaccination – vaccine – vaccinia – vaginal candidiasis – valley fever – variable region – varicella zoster virus (VZV) – vector – vertical transmission – viral burden – viral core – viral culture – viral envelope – viral load – viremia – viricide – virion – virology – virus – visceral
Low-boiling perfluoroalkanes are potent greenhouse gases, in part due to their very long atmospheric lifetime, and their use is covered by the Kyoto Protocol. The global warming potential (compared to that of carbon dioxide) of many gases can be found in the IPCC 5th assessment report, with an extract below for a few perfluoroalkanes.
Sources: en.wikipedia.org
== Theoretical Analysis of an Ideal Penning Trap == The motion of a single charged particle in an ideal Penning trap (with perfect alignment of its magnetic field to the quadrupole potential) is an exactly solvable system in both classical and quantum mechanics. The particle's motion along the trap's axis is simple harmonic motion, and the motion in the trap's xy-plane is a perturbation of cyclotron motion that reduces to cyclotron motion exactly in the zero-electric-field limit.
=== Withdrawal === Carisoprodol, meprobamate, and related drugs such as tybamate may produce physical dependence of the barbiturate type after prolonged use. Withdrawal after extensive use may require hospitalization in medically compromised patients. In severe cases the withdrawal can mimic the symptoms of alcohol withdrawal, including the potentially lethal status epilepticus. Psychological dependence has also been linked to carisoprodol use. Psychological dependence is more common in those who use carisoprodol non-medically and those who have a history of substance use (particularly sedatives or alcohol). It may reach clinical significance before physiological tolerance and dependence have occurred and (as with benzodiazepines) has been demonstrated to persist in varying degrees of severity for months or years after discontinuation. Discontinuation of carisoprodol, as with all GABA-ergics, can result in cognitive changes that persist for weeks, months, or rarely even years, including greatly increased anxiety and depression, social withdrawal, hair-trigger agitation/aggression, chronic insomnia, new or aggravated (often illogical) phobias, reduced IQ, short- and long-term memory loss, and dozens of other sequelae. The effects, severity, and duration appear to be slightly dose-dependent but are mainly determined by the patient's pattern of use (taken as prescribed, taken in bulk doses, mixed with other drugs, a combination of the above, etc.).
== Sources == Broodbank, Cyprian (2013). The Making of the Middle Sea: A History of the Mediterranean from the Beginning to the Emergence of the Classical World. London: Thames & Hudson. ISBN 978-0-500-29208-2. Brown, K.; Fa, D. A.; Finlayson, G.; Finlayson, C. (2011). "Small game and marine resource exploitation by Neanderthals: the evidence from Gibraltar". Trekking the shore: changing coastlines and the antiquity of coastal settlement. Interdisciplinary contributions to archaeology. Springer. ISBN 978-1-4419-8218-6. Finlayson, C. (2019). The smart Neanderthal: bird catching, cave art, and the cognitive revolution. Oxford University Press. ISBN 978-0-19-251812-5. French, Jennifer (2021). Palaeolithic Europe: A Demographic and Social Prehistory. Cambridge University Press. ISBN 978-1-108-49206-5. Papagianni, D.; Morse, M. A. (2013). "Still with us?". Neanderthals rediscovered: how modern science is rewriting their story. Thames and Hudson. ISBN 978-0-500-77311-6. Reich, D. (2018). "Encounters with Neanderthals". Who we are and how we got here: ancient DNA and the new science of the human past. Oxford University Press. ISBN 978-0-19-882125-0. Shipman, P. (2015). "How humans and their dogs drove Neanderthals to extinction". The invaders: how humans and their dogs drove Neanderthals to extinction. Harvard University Press. doi:10.2307/j.ctvjf9zbs. ISBN 978-0-674-42538-5. JSTOR j.ctvjf9zbs. Tattersall, I. (2015). "Neanderthals, DNA, and creativity". The strange case of the Rickety Cossack: and other cautionary tales from human evolution. St. Martin's Publishing Group.
Vitamin B12 deficiency can potentially cause severe and irreversible damage, especially to the brain and nervous system. At levels only slightly below normal, deficiency can result in fatigue, headaches, feeling faint, rapid breathing, pale skin, numbness or tingling, poor appetite, heartburn, poor balance, difficulty walking, poor reflexes, blurred vision, memory problems, depression, irritability, inattention, cognitive decline, dementia, and even psychosis. Among other problems, weakened immunity, reduced fertility and interruption of blood circulation in women may occur. It has also been linked to optic nerve atrophy and neuritis. The main type of vitamin B12 deficiency anemia is pernicious anemia, characterized by a triad of symptoms:
Many derivatives and structural analogs of modafinil have been synthesized. Examples include adrafinil, CE-123, fladrafinil (CRL-40941; fluorafinil), flmodafinil (CRL-40940; bisfluoromodafinil, lauflumide), RDS03-94, JJC8-088, modafiendz and modafinil sulfone.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.